Wall Street Zen Upgrades Cellebrite DI (NASDAQ:CLBT) to Hold

Cellebrite DI (NASDAQ:CLBT) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Other analysts also recently issued research reports about the stock. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Trading Down 0.6%

CLBT stock opened at $14.44 on Friday. The stock has a market cap of $3.60 billion, a P/E ratio of 46.58, a P/E/G ratio of 2.21 and a beta of 1.30. The stock’s fifty day simple moving average is $15.27 and its two-hundred day simple moving average is $16.91. Cellebrite DI has a 1-year low of $11.76 and a 1-year high of $20.86.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The firm had revenue of $128.82 million during the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business’s revenue was up 28.8% compared to the same quarter last year. During the same period last year, the firm posted $0.10 EPS. As a group, analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CLBT. Voss Capital LP increased its holdings in Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock worth $145,142,000 after acquiring an additional 1,277,300 shares during the last quarter. Pertento Partners LLP lifted its holdings in Cellebrite DI by 28.2% during the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the last quarter. Invesco Ltd. lifted its holdings in Cellebrite DI by 0.8% during the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after purchasing an additional 43,041 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Cellebrite DI by 17.1% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after purchasing an additional 570,000 shares during the period. Finally, Granahan Investment Management LLC boosted its position in Cellebrite DI by 16.3% during the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.